|Bid||70.96 x 300|
|Ask||74.00 x 100|
|Day's Range||71.04 - 71.86|
|52 Week Range||55.87 - 72.51|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.35%|
Novartis got government approval for a new cancer therapy. The treatment will cost a staggering $475,000, and it will help children and young adults with a certain type of Leukemia. Yahoo Finance's Seana Smith, Nicole Smith and Rick Newman react to what Wall Street is saying about the drug.
The healthcare sector is the second-best performer in the S&P 500 this year behind technology. Traditional, diversified healthcare exchange traded funds are delivering for investors. Just look at the Health ...
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Medical related ETFs have racked up healthy gains this year amid the ongoing quest for longer and healthier lives.